Literature DB >> 15489866

Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.

H J Kang1, H Y Shin, H S Choi, H S Ahn.   

Abstract

Antithymocyte globulin (ATG) has been used in severe aplastic anemia (SAA) as a part of the conditioning regimen. Among the many kinds of ATG preparations, thymoglobulin had been found to be more effective in preventing GVHD and rejection of organ transplants. As the fludarabine-based conditioning regimens without total body irradiation have been reported to be promising for bone marrow transplantation (BMT) from alternative donors in SAA, thymoglobulin was added to fludarabine and cyclophosphamide conditioning to reduce GVHD and to allow good engraftment in unrelated BMT. Five patients underwent BMT with cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 and -6), fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 and -2) and thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 and -1) from HLA-matched unrelated donors. Complete donor type hematologic recovery was achieved in all patients. No serious complication occurred during BMT. Only one patient developed grade I acute GVHD resolved spontaneously. Except for one who had rupture of hepatic adenoma 78 days after BMT, all the other four patients are still alive with median 566 days. Fludarabine, cyclophosphamide plus thymoglobulin conditioning allows for the promising results of good engraftment, tolerable toxicity and minimal GVHD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15489866     DOI: 10.1038/sj.bmt.1704720

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

Review 1.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

2.  Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.

Authors:  Chayamon Takpradit; Susan E Prockop; Nancy A Kernan; Andromachi Scaradavou; Kevin Curran; Julianne Ruggiero; Nicole Zakak; Richard J O'Reilly; Farid Boulad
Journal:  J Pediatr Hematol Oncol       Date:  2018-05       Impact factor: 1.289

Review 3.  Current concepts in the pathophysiology and treatment of aplastic anemia.

Authors:  Neal S Young; Rodrigo T Calado; Phillip Scheinberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

4.  Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia.

Authors:  Asha Pillai; Christine Hartford; Chong Wang; Deqing Pei; Jie Yang; Ashok Srinivasan; Brandon Triplett; Mari Dallas; Wing Leung
Journal:  Pediatr Transplant       Date:  2011-07-15

5.  Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia.

Authors:  Paolo Anderlini; Sandra A Acholonu; Grace-Julia Okoroji; Roland E Bassett; Elizabeth J Shpall; Muzaffar H Qazilbash; Uday R Popat; Laura L Worth; Sergio A Giralt; Richard E Champlin
Journal:  Leuk Lymphoma       Date:  2010-10-12

6.  Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation.

Authors:  Thissiane L Gonçalves; Dalila M Benvegnú; Gabriela Bonfanti
Journal:  Oxid Med Cell Longev       Date:  2009 Apr-Jun       Impact factor: 6.543

7.  Feasibility and results of bone marrow transplantation from an HLA-mismatched unrelated donor for children and young adults with acquired severe aplastic anemia.

Authors:  Hiroshi Yagasaki; Yoshiyuki Takahashi; Kazuko Kudo; Haruhiko Ohashi; Asahito Hama; Tomoko Yamamoto; Makito Tanaka; Nao Yoshida; Hirokazu Hidaka; Nobuhiro Nishio; Seiji Kojima
Journal:  Int J Hematol       Date:  2007-06       Impact factor: 2.490

Review 8.  Myelodysplasia and acute leukemia as late complications of marrow failure: future prospects for leukemia prevention.

Authors:  Grover C Bagby; Gabrielle Meyers
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

9.  Unrelated bone marrow transplantation with a reduced toxicity myeloablative conditioning regimen in Wiskott-Aldrich syndrome.

Authors:  Hyoung Jin Kang; Hee Young Shin; Sun Hie Ko; Jeong Ah Park; Eun Kyung Kim; Jung Woo Rhim; Joong Gon Kim; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2008-02       Impact factor: 2.153

10.  Successful salvage unrelated umbilical cord blood transplantation with two units after engraftment failure with single unit in severe aplastic anemia.

Authors:  Ji Won Lee; Hyoung Jin Kang; Eun Kyung Kim; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.